Overexpressed exogenous IL-4 and IL-10 paradoxically regulate allogenic T-Cell and cardiac myocytes apoptosis through FAS/FASL pathway

Transplantation

Volumn 85, Issue 3, 2008, Pages 437-446

  Furukawa, Hiroshi ^a   Oshima, Kiyohiro ^a   Tung, Thomas ^a   Cui, Guanggen ^a   Laks, Hillel ^a   Sen, Luyi ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Cardiac allograft rejection; Gene therapy; IL 10; IL 4

Indexed keywords

CASPASE 3; CASPASE 8; FAS ANTIGEN; FAS LIGAND; LIPOSOME; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 4;

ALLOIMMUNITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GRAFT SURVIVAL; HEART GRAFT; HEART MUSCLE CELL; HEART TRANSPLANTATION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; FAS LIGAND PROTEIN; GENE EXPRESSION REGULATION; GENE THERAPY; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; INTERLEUKIN-10; INTERLEUKIN-4; MALE; MYOCYTES, CARDIAC; RABBITS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 40049088488     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31816026e7     Document Type: Article

References (47)

1. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991; 147: 3815.
2. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209.
3. Bogdan C, Vodovotz Y, Nathan C. Macrophage deactivation by interleukin 10. J Exp Med 1991; 174: 1549.
4. Wang P, Wu P, Anthes JC, Siegel MI, Egan RW, Billah MM. Interleukin-10 inhibits interleukin-8 production in human neutrophils. Blood 1994; 83: 2678.
5. te Velde AA, Hujibens RJF, Heije K, de Vries JE, Figdor CG. Interleukin-4 (IL-4) inhibits secretion of IL-1β, tumor necrosis factor α, and IL-6 by human monocytes. Blood 1990; 76: 1392.
6. Hart PH, Vitti GF, Burgess DR, Whitty GA, Piccoli DS, Hamilton JA. Potential antiinflammatory effects of interleukin 4: Suppression of human monocyte tumor necrosis factor α, interleukin 1, and prostaglandin E2. Proc Natl Acad Sci USA 1989; 86: 3803.
7. Bogdan C, Vodovotz Y, Paik J, Xie Q, Nathan C. Mechanism of suppression of nitric oxide synthase expression by interleukin-4 in primary mouse macrophages. J Leukoc Biol 1994; 55: 227.
8. Abramson SL, Gallin JL. IL-4 inhibits superoxide production by human mononuclear phagocytes. J Immunol 1990; 144: 625.
9. Morris SC, Gause WC, Finkelman FD. IL-4 suppression of in vivo T cell activation and antibody production. J Immunol 2000; 164: 1734.
10. Oswald IP, Gazzinelli RT, Sher A, James SL. IL-10 synergizes with IL-4 and transforming growth factor-β to inhibit macrophage cytotoxic activity. J Immunol 1992; 148: 3578.
11. Powrie F, Menon S, Coffman RL. Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo. Eur J Immunol 1993; 23: 2223.
12. Yamakami K, Akao S, Tadakuma T, Nitta Y, Miyazaki J, Yoshizawa N. Administration of plasmids expressing interleukin-4 and interleukin-10 causes BALB/c mice to induce a T helper 2-type response despite the expected T helper 1-type response with a low-dose infection of Leishmania major. Immunology 2002; 105: 515.
13. Rabinovitch A, Suarez-Pinzon WL, Sorensen O, Bleackley RC, Power RF, Rajotte RV. Combined therapy with interleukin-4 and interleukin-10 inhibits autoimmune diabetes recurrence in syngeneic islet-transplanted nonobese diabetic mice. Transplantation 1995; 60: 368.
14. Faust A, Rothe H, Schade U, Lampeter E, Kolb H. Primary nonfunction of islet grafts autoimmune diabetic nonobese diabetic mice is prevented by treatment with interleukin-4 and interleukin-10. Transplantation 1996; 62: 648.
15. Ko KS, Lee M, Koh JJ, Kim SW. Combined administration of plasmids encoding IL-4 and IL-10 prevents the development of autoimmune diabetes in nonobese diabetic mice. Mol Ther 2001; 4: 313.
16. Furukawa H, Oshima K, Russell H, et al. Liposome-mediated combinatorial cytokine gene therapy induces localized synergistic immunosuppression and promotes long-term survival of cardiac allografts. J Immun 2005; 174: 6983.
17. Rogy MA, Beinhauer BG, Reinisch W, Huang L, Pokieser P. Transfer of interleukin-4 and interleukin-10 in patients with severe inflammatory bowel disease of the rectum. Hum Gene Ther 2000; 11: 1731.
18. Miller L, Granville DJ, Narula J, McManus BM. Apoptosis in cardiac transplant rejection. Cardiol Clin 2001; 19: 141.
19. Kägi D, Vignaux F, Ledermann B, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265: 528.
20. Takeuchi T, Ueki T, Nishimatsu H, et al. Accelerated rejection of Fas ligand-expressing heart grafts. J Immunol 1999; 162: 518.
21. Oh SI, Kim IW, Jung HC, et al. Correlation of Fas and Fas ligand expression with rejection status of transplanted heart in human. Transplantation 2001; 71: 906.
22. Sen L, Hong YS, Luo H, Cui G, Laks H. Efficiency, efficacy, and adverse effects of adenovirus- vs. liposome-mediated gene therapy in cardiac allografts. Am J Physiol Heart Circ Physiol 2001; 281: H1433.
23. Oshima K, Sen L, Cui G, et al. Localized interleukin-10 gene transfer induces apoptosis of alloreactive T cells via Fas/FasL pathway, improves function, and prolongs survival of cardiac allograft. Transplantation 2002; 73: 1019.
24. Hong YS, Laks H, Cui G, Chong T, Sen L. Localized immunosuppression in the cardiac allograft induced by a new liposome-mediated IL-10 gene therapy. J Heart Lung Transplant 2002; 21: 1188.
25. Sen L, Gambhir SS, Furukawa H, Stout D, Laks H, Cui G. Quantitative and noninvasive imaging nonviral therapeutic transgene expression in myocardium. Mol Ther 2005; 12: 49.
26. Billingham ME, Cary NRB, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart rejection study group. J Heart Lung Transplant 1990; 9: 587.
27. +-T-cell apoptosis during Schistosomal infection: Induction by interleukin 4 (IL-4) and IL-10. Infect Immun 2002; 70: 812.
28. Woods JM, Katscke KJ Jr, Volin MV, et al. IL-4 adenoviral gene therapy reduces inflammation, proinflammatory cytokines, vascularization, and bony destruction in rat adjuvant-induced arthritis. J Immunol 2001; 166: 1214.
29. Hogaboam CM, Vallance BA, Kumar A, et al. Therapeutic effects of interleukin-4 gene transfer in experimental inflammatory bowel disease. J Clin Invest 1997; 100: 2766.
30. Yamamoto AM, Chernajovsky Y, Lepault F, et al. The activity of immunoregulatory T cells mediating active tolerance is potentiated in nonobese diabetic mice by an IL-4-based retroviral gene therapy. J Immunol 2001; 166: 4973.
31. Levy AE, Alexander JW. Administration of intragraft interleukin-4 prolongs cardiac allograft survival in rats treated with donor-specific transfusion/cyclosporine. Transplantation 1995; 60: 405.
32. Li XC, Wells AD, Strom TB, Turka LA. The role of T cell apoptosis in transplantation tolerance. Curr Opin Immunol 2000; 12: 522.
33. Tung TC, Oshima K, Cui G, Laks H, Sen L. Dual upregulation of surface Fas and mitochondrial Bax promotes alloreactive T cell apoptosis in interleukin-10 gene targeting of cardiac allografts. Am J Physiol Heart Circ Physiol 2003; 285: H964.
34. Georgescu L, Vakkalanka RK, Elkon KB, Crow MK. Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand. J Clin Invest 1997; 100: 2622.
35. Schimidt M, Lügering N, Pauels HG, Schulze-Osthoff K, Domschke W, Kucharzik T. IL-10 induces apoptosis in human monocytes involving the CD95 receptor/ligand pathway. Eur J Immunol 2000; 30: 1769.
36. Aung S, Graham BS. IL-4 diminishes perforin-mediated and increases Fas ligand-mediated cytotoxicity in vivo. J Immunol 2000; 164: 3487.
37. Punch JD, Tono T, Qin L, Bishop DK, Bromberg JS. Tolerance induction by anti-CD2 plus anti-CD3 monoclonal antibodies: Evidence for an IL-4 requirement. J Immunol 1998; 161: 1156.
38. Yeatman CF II, Jacobs-Helber SM, Mirmonsef P, et al. Combined stimulation with the T helper cell type 2 cytokines interleukin (IL)-4 and IL-10 induces mouse mast cell apoptosis. J Exp Med 2000; 192: 1093.
39. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630.
40. + T cells via Fas/Fas ligand-mediated apoptosis. J Immunol 1997; 158: 1503.
41. + cytotoxic T cells. Proc Natl Acad Sci USA 1994; 91: 4185.
42. + T cell-mediated cytotoxicity. J Immunol 1994; 152: 1127.
43. Kabelitz D. Apoptosis, graft rejection, and transplantation tolerance. Transplantation 1998; 65: 869.
44. Szabolcs M, Micheler RE, Yang X, et al. Apoptosis of cardiac myocytes during cardiac allograft rejection - Relation to induction on nitric oxide synthase. Circulation 1996; 94: 1665.
45. Laguens RP, Meckert PMC, Martino JS, Perrone S, Favaloro R. Identification of programmed cell death (apoptosis) in situ by means of specific labeling of nuclear DNA fragments in heart biopsy samples during acute rejection episodes. J Heart Lung Transplant 1996; 15: 911.
46. + T cells promote inflammation and apoptosis in the liver after sepsis: role of Fas-FasL. Am J Pathol 2007; 171: 87.
47. Raghavendra PB, Sreenivasan Y, Ramesh GT, Manna SK. Cardiac glycoside induces cell death through FasL by activating calcineurin and NF-AT, but apoptosis initially proceeds through activation of caspases. Apoptosis 2007; 12: 307.